Pre-Made Tagraxofusp biosimilar, Protein drug conjugate: Recombinant therapeutic protein drug conjugate for drug discovery and mechanism of action (MOA) research

Recombinant therapeutic protein drug conjugate (Pre-made Tagraxofusp biosimilar, Protein drug conjugate) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).[3][4] It was approved for use in the United States in 218,[5] and after a second review, in the EU in January 221.[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6] Tagraxofusp is an engineered molecule composed of Diptheria toxin covalently attached to a portion of the interleukin-3 cytokine. The drug binds to the β-chain of the interleukin-3 receptor (CD123), which mediates endocytosis.51 The Diptheria toxin is subsequently released and induces cytotoxicity through protein inhibition.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1003-1mg	1mg	3090
GMP-Bios-INN-1003-10mg	10mg	Inquiry
GMP-Bios-INN-1003-100mg	100mg	Inquiry
GMP-Bios-INN-1003-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tagraxofusp biosimilar, Protein drug conjugate: Recombinant therapeutic protein drug conjugate
INN Name	Tagraxofusp
Target	IL3
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - Corynebacterium diphtheriae toxin (Pr1, 26-411) - IL3 (interleukin 3, interleukin 3 (colony-stimulating factor, multiple))
VD LC	Fusion - Corynebacterium diphtheriae toxin (Pr1, 26-411) - IL3 (interleukin 3, interleukin 3 (colony-stimulating factor, multiple))
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Stemline Therapeutics Inc (New-York NY USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0